Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, San Diego
With
Navidea Biopharmaceuticals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
The patient has a diagnosis of biopsy-proven primary breast cancer or a diagnosis of pure ductal carcinoma in situ (DCIS) who will be undergoing intraoperative lymphatic mapping as part of their standard surgical plan.
The patient has provided written informed consent before participating in the study, as has his/her responsible caregiver, if applicable.
The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.
The patient is greater than 18 years of age at the time of consent.
The patient has an performance status of Grade 0 - 2.
The patient has a clinical negative node status at the time of study entry.
If the patients is of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of radiopharmaceutical, has been surgically sterilized, or has been postmenopausal for at least 1 year.
You may not be if
The patient is pregnant or lactating.
The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes
Clareo Health | Sentinel Lymph Node Mapping Post-Injection Site Pain
